Evaluating ctDNA Clearance in HR-Positive, HER2-Negative Advanced Breast Cancer

Dr. Seth Wander and Dr. Jason Mouabbi discuss the potential significance of circulating tumor DNA clearance as a marker of treatment response in HR-positive, HER2-negative advanced breast cancer. Dr. Wander reviews emerging data evaluating changes in overall ctDNA burden following biomarker-guided treatment adaptation and explains how ctDNA dynamics may provide broader insight into tumor activity beyond individual resistance mutations such as ESR1. The experts discuss how reductions in ctDNA levels may reflect changes in molecular disease burden and how ongoing research is exploring the relationship between ctDNA clearance and clinical outcomes. Dr. Mouabbi highlights the potential value of molecular monitoring in providing a more detailed understanding of tumor behavior alongside traditional imaging approaches. The discussion emphasizes the evolving role of ctDNA-based assessments in refining treatment strategies and advancing personalized care for patients with HR-positive, HER2-negative advanced breast cancer.